Stockhub

Editing X4 Pharmaceuticals, Inc.

Revision as of 20:08, 31 July 2022 by Chris (talk | contribs) (Created page with "X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Warning: You are editing an out-of-date revision of this page. If you publish it, any changes made since this revision will be lost.

Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see Stockhub:Copyrights for details). Do not submit copyrighted work without permission!
Cancel Editing help (opens in new window)
Retrieved from ‘https://stockhub.co/research/X4_Pharmaceuticals,_Inc.’